ReviewJournal of the American Academy of Dermatology2014
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
3 registry-linked trialsAbstract readReview
In one paragraph
Review in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 457 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
457citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Patient and Caregiver Quality of Life in the Treatment of Atopic Dermatitis in Pediatric Patients: a Comparison Between a General Pediatric Practice and a Pediatric Dermatology Practice
The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis
Efficacy and Safety of Baricitinib Versus Azathioprine in Combination With Topical Corticosteroids For Patients With Moderate-to-Severe Atopic Dermatitis
Who cites it
457 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany.Acta dermato-venereologica · 2026Pooled it
- Skin barrier-related genes in childhood atopic dermatitis, asthma, and allergy: A systematic review and meta-analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Pooled it
- Correlation betweenFrontiers in immunology · 2026Pooled it
- Risk of incident venous thromboembolism in patients with atopic dermatitis: systematic analysis of the literature and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Baricitinib as monotherapy and with topical corticosteroids in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of dose-response.Frontiers in allergy · 2024Pooled it
- Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Dermatology (Basel, Switzerland) · 2024Guideline
- Serum thymic stromal lymphopoietin (TSLP) levels in atopic dermatitis patients: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.BMC medicine · 2026Trial
- Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.Acta dermato-venereologica · 2026Trial
- Efficacy, Safety and Immunomodulatory Effect of Intramuscular Injections of Autologous Whole Blood Into Acupoints in Patients With Atopic Dermatitis: A Randomized Controlled Trial.Immunity, inflammation and disease · 2026Trial
- Clinical and Molecular Effect of the Anti-IL-18 Antibody Aletekitug in Adults With Atopic Dermatitis.Allergy · 2026Trial
- Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study.American journal of clinical dermatology · 2025Trial
- Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study.Nature communications · 2025Trial
- The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.Nature communications · 2024Trial
- Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.Clinical and translational science · 2023Trial
- Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).JAMA dermatology · 2023Trial
- Temporal Trends in Janus Kinase Inhibitor (JAKi) Use Across Five European Countries: A DARWIN EU Network Study.Pharmacoepidemiology and drug safety · 2026Article
- Long-Term Risk of Allergic Contact Dermatitis in Children With Atopic Respiratory Disease When They Reach Adulthood.Contact dermatitis · 2026Article
- Early Ocular-Surface Changes During Dupilumab Treatment According to Hyaluronic Acid Use: A Prospective Cohort Study.Journal of personalized medicine · 2026Article
397 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Lawrence F EichenfieldDivision of Pediatric and Adolescent Dermatology, Rady Children's Hospital San Diego, San Diego, California.
Wynnis L TomDivision of Pediatric and Adolescent Dermatology, Rady Children's Hospital San Diego, San Diego, California.
Sarah L ChamlinDepartment of Dermatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Steven R FeldmanDepartment of Dermatology, Wake Forest University Health Sciences, Winston-Salem, North Carolina.
Jon M HanifinDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
Timothy G BergerDepartment of Dermatology, University of California San Francisco, San Francisco, California.
James N BergmanDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
David E CohenRonald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.
Kevin D CooperDepartment of Dermatology, Case Western University, Cleveland, Ohio.
Kelly M CordoroDepartment of Dermatology, University of California San Francisco, San Francisco, California.
Dawn M DavisDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota.
Alfons KrolDepartment of Dermatology, Oregon Health and Science University, Portland, Oregon.
David J MargolisDepartment of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Amy S PallerDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Kathryn SchwarzenbergerDivision of Dermatology, Fletcher Allen Health Care, Burlington, Vermont.
Robert A SilvermanPrivate practice, Fairfax, Virginia.
Hywel C WilliamsCentre of Evidence-Based Dermatology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Craig A ElmetsDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.
Julie BlockNational Eczema Association, San Rafael, California.
Christopher G HarrodAmerican Academy of Dermatology, Schaumburg, Illinois.
Wendy Smith BegolkaAmerican Academy of Dermatology, Schaumburg, Illinois. Electronic address: wsmithbegolka@aad.org.
Robert SidburyDepartment of Dermatology, Seattle Children's Hospital, Seattle, Washington.
Funding
Genetic Influence in Pediatric PsoriasisK23AR060274 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TOM, WYNNIS L · 2011 to 2015
$663kNIAMS NIH HHS K23 AR060274NIAMS NIH HHS K23AR060274
Abstract
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.
Indexed as
Practice Guidelines as TopicQuality of LifeAdolescentAdultAge FactorsBiomarkersChildChronic DiseaseComorbidityDermatitis, AtopicEvidence-Based MedicineFemaleFilaggrin ProteinsHumansMalePhysical ExaminationBiomarkersFilaggrin ProteinsFLG protein, humanAADADADHDAmerican Academy of Dermatologyassessment scalesatopic dermatitisattention deficit hyperactivity disorderbiomarkersCDLQIChildren's Dermatology Life Quality Indexclinical associationscriteriaDermatitis Family ImpactDermatology Life Quality IndexDFIdiagnosisDLQIEASIEczema Area and Severity IndexfilaggrinFLGGlobal Resource for Eczema TrialsGREATIGAIgEILimmunoglobulin EinterleukinInternational Study of Asthma and Allergies in ChildhoodInvestigator's Global AssessmentISAACmacrophage-derived chemoattractantMDCPatient-Oriented Eczema MeasurePOEMrisk factorsSASSADSCORADSCORing Atopic DermatitisSix Area, Six Sign Atopic DermatitisSORTstrength of recommendation taxonomyTARCThree-Item Severity Scalethymus and activation-regulated chemokineTISSUKUnited Kingdom
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.